A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206)

Junko Eba, Hirotsugu Kenmotsu, Masahiro Tsuboi, Seiji Niho, Hiroshi Katayama, Taro Shibata, Shun ichi Watanabe, Noboru Yamamoto, Tomohide Tamura, Hisao Asamura

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A randomized Phase III trial commenced in Japan in March 2013. Post-operative adjuvant chemotherapy with etoposide plus cisplatin is the current standard treatment for resected pulmonary high-grade neuroendocrine carcinoma including small cell lung cancer and large cell neuroendocrine carcinoma. The purpose of this study is to confirm the superiority of irinotecan plus cisplatin in terms of overall survival over etoposide plus cisplatin as post-operative adjuvant chemotherapy for pathological Stage I-IIIA completely resected pulmonary high-grade neuroendocrine carcinoma patients. A total of 220 patients will be accrued from 54 Japanese institutions within 6 years. The primary endpoint is overall survival and the secondary endpoints are relapse-free survival, proportion of treatment completion, adverse events, serious adverse events and second malignancy.

Original languageEnglish
Article numberhyt233
Pages (from-to)379-382
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume44
Issue number4
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

irinotecan
Neuroendocrine Carcinoma
Etoposide
Adjuvant Chemotherapy
Cisplatin
Lung
Survival
Large Cell Carcinoma
Second Primary Neoplasms
Small Cell Lung Carcinoma
Japan
Recurrence
Therapeutics

Keywords

  • Adjuvant chemotherapy
  • High-grade neuroendocrine carcinoma
  • Lung neoplasms
  • Phase III

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206). / Eba, Junko; Kenmotsu, Hirotsugu; Tsuboi, Masahiro; Niho, Seiji; Katayama, Hiroshi; Shibata, Taro; Watanabe, Shun ichi; Yamamoto, Noboru; Tamura, Tomohide; Asamura, Hisao.

In: Japanese Journal of Clinical Oncology, Vol. 44, No. 4, hyt233, 2014, p. 379-382.

Research output: Contribution to journalArticle

Eba, Junko ; Kenmotsu, Hirotsugu ; Tsuboi, Masahiro ; Niho, Seiji ; Katayama, Hiroshi ; Shibata, Taro ; Watanabe, Shun ichi ; Yamamoto, Noboru ; Tamura, Tomohide ; Asamura, Hisao. / A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206). In: Japanese Journal of Clinical Oncology. 2014 ; Vol. 44, No. 4. pp. 379-382.
@article{732ca1f9f1d14d7490de972770fcfae4,
title = "A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206)",
abstract = "A randomized Phase III trial commenced in Japan in March 2013. Post-operative adjuvant chemotherapy with etoposide plus cisplatin is the current standard treatment for resected pulmonary high-grade neuroendocrine carcinoma including small cell lung cancer and large cell neuroendocrine carcinoma. The purpose of this study is to confirm the superiority of irinotecan plus cisplatin in terms of overall survival over etoposide plus cisplatin as post-operative adjuvant chemotherapy for pathological Stage I-IIIA completely resected pulmonary high-grade neuroendocrine carcinoma patients. A total of 220 patients will be accrued from 54 Japanese institutions within 6 years. The primary endpoint is overall survival and the secondary endpoints are relapse-free survival, proportion of treatment completion, adverse events, serious adverse events and second malignancy.",
keywords = "Adjuvant chemotherapy, High-grade neuroendocrine carcinoma, Lung neoplasms, Phase III",
author = "Junko Eba and Hirotsugu Kenmotsu and Masahiro Tsuboi and Seiji Niho and Hiroshi Katayama and Taro Shibata and Watanabe, {Shun ichi} and Noboru Yamamoto and Tomohide Tamura and Hisao Asamura",
year = "2014",
doi = "10.1093/jjco/hyt233",
language = "English",
volume = "44",
pages = "379--382",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206)

AU - Eba, Junko

AU - Kenmotsu, Hirotsugu

AU - Tsuboi, Masahiro

AU - Niho, Seiji

AU - Katayama, Hiroshi

AU - Shibata, Taro

AU - Watanabe, Shun ichi

AU - Yamamoto, Noboru

AU - Tamura, Tomohide

AU - Asamura, Hisao

PY - 2014

Y1 - 2014

N2 - A randomized Phase III trial commenced in Japan in March 2013. Post-operative adjuvant chemotherapy with etoposide plus cisplatin is the current standard treatment for resected pulmonary high-grade neuroendocrine carcinoma including small cell lung cancer and large cell neuroendocrine carcinoma. The purpose of this study is to confirm the superiority of irinotecan plus cisplatin in terms of overall survival over etoposide plus cisplatin as post-operative adjuvant chemotherapy for pathological Stage I-IIIA completely resected pulmonary high-grade neuroendocrine carcinoma patients. A total of 220 patients will be accrued from 54 Japanese institutions within 6 years. The primary endpoint is overall survival and the secondary endpoints are relapse-free survival, proportion of treatment completion, adverse events, serious adverse events and second malignancy.

AB - A randomized Phase III trial commenced in Japan in March 2013. Post-operative adjuvant chemotherapy with etoposide plus cisplatin is the current standard treatment for resected pulmonary high-grade neuroendocrine carcinoma including small cell lung cancer and large cell neuroendocrine carcinoma. The purpose of this study is to confirm the superiority of irinotecan plus cisplatin in terms of overall survival over etoposide plus cisplatin as post-operative adjuvant chemotherapy for pathological Stage I-IIIA completely resected pulmonary high-grade neuroendocrine carcinoma patients. A total of 220 patients will be accrued from 54 Japanese institutions within 6 years. The primary endpoint is overall survival and the secondary endpoints are relapse-free survival, proportion of treatment completion, adverse events, serious adverse events and second malignancy.

KW - Adjuvant chemotherapy

KW - High-grade neuroendocrine carcinoma

KW - Lung neoplasms

KW - Phase III

UR - http://www.scopus.com/inward/record.url?scp=84897475114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897475114&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyt233

DO - 10.1093/jjco/hyt233

M3 - Article

VL - 44

SP - 379

EP - 382

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 4

M1 - hyt233

ER -